Zevra Therapeutics (ZVRA) Intangibles (2023 - 2026)

Zevra Therapeutics has reported Intangibles for 4 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 89.82% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (down 89.82% YoY), and the FY2025 full-year result was $6.4 million, down 90.69% from the prior year.
• Intangibles for Q1 2026 stood at $6.1 million, down from $6.4 million in the prior quarter.
• The five-year high for Intangibles was $70.6 million in Q3 2024, with the low at $2.0 million in Q4 2023.
• Historically, Intangibles has averaged $23.2 million across 4 years, with a median of $6.6 million in 2025.
• Annual changes were most pronounced in 2024 — Intangibles jumped 3349.65% — and 2025, when it sank 90.69%.
• Zevra Therapeutics' Intangibles stood at $2.0 million in 2023, then jumped by 3349.65% to $69.0 million in 2024, then slumped by 90.69% to $6.4 million in 2025, then fell by 4.92% to $6.1 million in 2026.
• The last three Intangibles figures came in at $6.1 million (Q1 2026), $6.4 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.